# P1 extraction audit packet (round 2)

These 22 turns were rescued by the any-number extraction rule but the target value is not the final asserted number (after ignoring quarter/year tokens, bold answers, and the closing 200 characters). For each, decide whether the response's FINAL answer equals the target within tolerance (1% or the stated absolute tolerance). Record verdicts in the JSON field author_verdict_final_answer_correct.

## 1. claude-sonnet-4.5 P1_015 T20 (correction_verify, probe) target = 28.0

```
| 40.2 |
| Q1 2024 | 34.8 |
| Q2 2024 | 34.4 |

**Answer: Q3 2023 still had the lowest gross profit at $28.6M**

The correction to Q4 2022 doesn't change this answer - it only makes Q4 2022's gross profit higher ($47.9M instead of $36.8M), so Q3 2023 remains the quarter with the lowest gross profit.
```

## 2. claude-sonnet-4.5 P1_044 T20 (correction_verify, probe) target = 32.56

```
4.4M) ÷ 7

**Average Net Income** = $230.3M ÷ 7 = **$32.90M**

---

**Answer:** With the corrected COGS, the average net income across quarters where COGS exceeded $27.5M was **$32.90 million** (down from the originally calculated $33.92 million, due to including Q3 2023 which had lower net income).
```

## 3. gemini-2.5-pro P1_004 T2 (count_above) target = 8.0

```
ting expenses exceeded $11.1M in all 8 quarters provided.

Here are the operating expenses for each quarter:
*   **Q1 2023:** $12.2M
*   **Q2 2023:** $12.0M
*   **Q3 2023:** $13.1M
*   **Q4 2023:** $14.2M
*   **Q1 2024:** $12.6M
*   **Q2 2024:** $13.0M
*   **Q3 2024:** $13.3M
*   **Q4 2024:** $15.3M
```

## 4. gemini-2.5-pro P1_006 T15 (conditional_aggregate, probe) target = 111.8

```
2 2023:** $6.8M / $28.6M = 23.8%
*   **Q3 2023:** $7.0M / $28.4M = 24.6%
*   **Q4 2023:** $8.0M / $33.0M = 24.2%
*   **Q1 2024:** $8.0M / $32.8M = 24.4%
*   **Q2 2024:** $7.7M / $31.4M = 24.5%
*   **Q3 2024:** $8.2M / $33.3M = 24.6%
*   **Q4 2024:** $9.4M / $37.0M = 25.4%
*   **Q1 2025:** $8.6M / $3
```

## 5. gemini-2.5-pro P1_011 T20 (correction_verify, probe) target = 7.0

```
n, the operating expenses for Q4 2022 ($13.4M) are still above the $12.5M threshold, so the total number of quarters remains the same.

These quarters were:
*   Q4 2022: **$13.4M**
*   Q1 2023: $13.0M
*   Q2 2023: $13.2M
*   Q3 2023: $13.6M
*   Q4 2023: $16.7M
*   Q1 2024: $15.4M
*   Q2 2024: $16.7M
```

## 6. gemini-2.5-pro P1_027 T4 (count_above) target = 6.0

```
Jasper Sciences's revenue exceeded $54.8M in **6 quarters**.

The quarters that exceeded this amount were:
*   **Q4 2022:** $58.1M
*   **Q4 2023:** $62.7M
*   **Q1 2024:** $56.5M
*   **Q2 2024:** $56.9M
*   **Q3 2024:** $62.2M
*   **Q4 2024:** $69.1M
```

## 7. gemini-2.5-pro P1_028 T15 (conditional_aggregate, probe) target = 194.7

```
uarters where COGS was below 45% of revenue was $194.7 million.

**Calculation:**

1.  **Identify quarters where COGS was below 45% of Revenue:**
    *   Q2 2023: $34.2M / $76.8M = 44.5%
    *   Q1 2024: $37.6M / $85.9M = 43.8%
    *   Q3 2024: $43.6M / $97.2M = 44.9%
    *   Q4 2024: $50.3M / $114.
```

## 8. gemini-2.5-pro P1_033 T3 (count_above) target = 8.0

```
Prism Therapeutics's operating expenses exceeded $13.0M in all 8 quarters provided.

The operating expenses for each quarter were:
*   Q1 2022: $13.3M
*   Q2 2022: $13.5M
*   Q3 2022: $14.3M
*   Q4 2022: $14.3M
*   Q1 2023: $14.6M
*   Q2 2023: $14.6M
*   Q3 2023: $15.4M
*   Q4 2023: $18.3M
```

## 9. gemini-2.5-pro P1_033 T20 (correction_verify, probe) target = 8.0

```
hat threshold.

Here is the updated list of operating expenses for each quarter:
*   Q1 2022: $13.3M
*   Q2 2022: $13.5M
*   Q3 2022: $14.3M
*   Q4 2022: **$16.8M** (Corrected)
*   Q1 2023: $14.6M
*   Q2 2023: $14.6M
*   Q3 2023: $15.4M
*   Q4 2023: $18.3M

All eight figures are greater than $13.0M.
```

## 10. gemini-2.5-pro P1_049 T20 (correction_verify, probe) target = 5.0

```
3 is **$34.2M**, which is still below the $34.7M threshold. Therefore, the list of quarters exceeding the threshold does not change.

The quarters that exceeded $34.7M in COGS are:
*   **Q2 2024:** $35.3M
*   **Q3 2024:** $35.5M
*   **Q4 2024:** $40.1M
*   **Q1 2025:** $37.7M
*   **Q2 2025:** $45.8M
```

## 11. gemini-2.5-pro P1_050 T2 (count_above) target = 9.0

```
Onyx Logistics's gross profit exceeded $27.3M in 9 quarters.

These quarters were:
*   Q4 2022 ($29.0M)
*   Q1 2023 ($28.5M)
*   Q2 2023 ($28.0M)
*   Q3 2023 ($31.4M)
*   Q4 2023 ($37.2M)
*   Q1 2024 ($29.1M)
*   Q2 2024 ($38.2M)
*   Q3 2024 ($40.8M)
*   Q4 2024 ($46.6M)
```

## 12. gpt-4o P1_007 T14 (conditional_average) target = 15.35

```
ere revenue exceeded $34.2M.

### Average Net Income:
\[
\text{Average Net Income} = \frac{\text{Total Net Income}}{\text{Number of Quarters}} = \frac{80.8}{5} = 16.16 \, \text{million}
\]

### Final Answer:
The average net income across quarters where revenue exceeded $34.2M was **$16.16 million**.
```

## 13. gpt-4o P1_030 T20 (correction_verify, probe) target = 520.8

```
Answer:
The total revenue across quarters where operating expenses were below 50% of revenue is **$521.8M**.  

This result remains **unchanged** from the earlier calculation because the corrected operating expenses for **Q4 2023** still satisfy the condition **Operating Expenses < 50% of Revenue**.
```

## 14. gpt-4o P1_043 T13 (conditional_average) target = 22.85

```
es}}{\text{Number of Quarters}}
\]

\[
\text{Sum of Operating Expenses} = 23.2 + 22.8 + 24.0 = 70.0 \, \text{M}
\]

\[
\text{Average Operating Expenses} = \frac{70.0}{3} \approx 23.33 \, \text{M}
\]

The average operating expenses across quarters where revenue exceeded $85.3M was **$23.33 million**.
```

## 15. gpt-4o P1_048 T12 (conditional_average) target = 7.38

```
}{\text{Number of Quarters}}
\]
\[
\text{Average Operating Expenses} = \frac{8.6 + 7.1 + 8.1}{3}
\]
\[
\text{Average Operating Expenses} = \frac{23.8}{3} = 7.93 \, \text{($M)}
\]

### Conclusion:
Elara Energy's average operating expenses across quarters where **COGS exceeded $14.6M** was **$7.93M**.
```

## 16. deepseek-r1 P1_008 T4 (count_above) target = 8.0

```
ters had operating expenses exceeding $5.2M.

**Explanation:**  
The operating expenses for each quarter are:  
- Q1 2022: $5.9M  
- Q2 2022: $6.2M  
- Q3 2022: $6.5M  
- Q4 2022: $6.3M  
- Q1 2023: $7.0M  
- Q2 2023: $6.6M  
- Q3 2023: $7.5M  
- Q4 2023: $10.5M  

All values are greater than $5.2M.
```

## 17. deepseek-r1 P1_030 T20 (correction_verify, probe) target = 520.8

```
023: 15.1 / 57.6 ≈ 26.2%
- Q2 2023: 14.5 / 56.4 ≈ 25.7%
- Q3 2023: 15.9 / 58.7 ≈ 27.1%
- Q4 2023: 16.3 / 68.9 ≈ 23.7%
- Q1 2024: 16.8 / 63.0 ≈ 26.7%
- Q2 2024: 16.9 / 66.3 ≈ 25.5%
- Q3 2024: 16.8 / 65.1 ≈ 25.8%
- Q4 2024: 21.9 / 84.8 ≈ 25.8%

All are below 50%, so the total revenue sum is unchanged.
```

## 18. deepseek-r1 P1_033 T3 (count_above) target = 8.0

```
Prism Therapeutics's operating expenses exceeded $13.0M in all 8 quarters.

**Count**:  
- Q1 2022: $13.3M  
- Q2 2022: $13.5M  
- Q3 2022: $14.3M  
- Q4 2022: $14.3M  
- Q1 2023: $14.6M  
- Q2 2023: $14.6M  
- Q3 2023: $15.4M  
- Q4 2023: $18.3M  

All values are greater than $13.0M.
```

## 19. deepseek-r1 P1_045 T20 (correction_verify, probe) target = 51.5

```
 2025:** 67.1 – 15.6 = **51.5**  
- **Q4 2024:** 67.7 – 16.3 = 51.4  
- **Q3 2024:** 62.6 – 14.8 = 47.8  
- **Q4 2023:** 62.2 – 14.7 = 47.5  
- **Q3 2023 (corrected):** 53.5 – 10.7 = 42.8  
- Other quarters are lower.

The correction did not change the ranking—Q2 2025 still holds the largest margin.
```

## 20. deepseek-r1 P1_047 T20 (correction_verify, probe) target = 6.0

```
arters where COGS exceeds $20.8M remains **6 quarters**.

**Quarters with COGS > $20.8M:**
- Q4 2023: $22.0M
- Q2 2024: $21.1M
- Q3 2024: $22.8M
- Q4 2024: $34.2M
- Q1 2025: $27.6M
- Q2 2025: $27.4M

The corrected COGS for Q3 2023 ($20.5M) does not exceed $20.8M, so the list and count are unchanged.
```

## 21. minimax-m2.5 P1_017 T15 (conditional_aggregate, probe) target = 74.7

```
022: $5.3M
- Q2 2022: $5.5M
- Q3 2022: $5.6M
- Q4 2022: $5.7M
- Q1 2023: $6.1M
- Q2 2023: $5.9M
- Q3 2023: $5.8M
- Q4 2023: $7.4M
- Q1 2024: $6.4M
- Q2 2024: $6.5M
- Q3 2024: $6.7M
- Q4 2024: $7.8M

**Total: $5.3 + $5.5 + $5.6 + $5.7 + $6.1 + $5.9 + $5.8 + $7.4 + $6.4 + $6.5 + $6.7 + $7.8 = $68.0M**
```

## 22. minimax-m2.5 P1_027 T15 (conditional_aggregate, probe) target = 56.8

```
69.1M = 44.57% — Below 45% ✓

Now, summing R&D spending for the qualifying quarters:

- Q1 2022: $6.1M
- Q2 2022: $5.7M
- Q3 2022: $6.1M
- Q4 2022: $6.8M
- Q2 2023: $4.9M
- Q1 2024: $6.0M
- Q2 2024: $6.0M

Total R&D spending = $6.1M + $5.7M + $6.1M + $6.8M + $4.9M + $6.0M + $6.0M = **$41.6 million**
```

